Spero Therapeutics, Inc.
NMS: SPROLive Quote
About Spero Therapeutics, Inc.
Healthcare
Biotechnology
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candidate for first-line treatment of nontuberculous mycobacterial (NTM) pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to the oral prodrug SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
📊 Fundamental Analysis
Spero Therapeutics, Inc. demonstrates a healthy profit margin of 12.8%.
The company recently reported 174.5% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is 16.3%, which suggests room for improvement in capital utilization.
At a current price of $2.67, SPRO currently sits at the 79th percentile of its 52-week range (Range: $0.57 - $3.22).
💰 Valuation Insight
SPRO is valued broadly in line with the sector at a PE of 17.80. Analysts expect earnings growth, as indicated by a lower forward PE.
🏥 Financial Health
⚠️
Profit Margin
Moderate
🔴
Debt/Equity
Elevated
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$158.65M
Trailing P/E
17.80
Forward P/E
-2.41
Beta (5Y)
1.45
52W High
$3.22
52W Low
$0.57
Avg Volume
343K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App